82.1 F
San Fernando
Saturday, Jun 3, 2023

Amgen Heart Drug Wins Fast-Track Status

The U.S. Food and Drug Administration has granted fast-track designation for ivabradine, a heart drug licensed for sale by Amgen Inc. in Thousand Oaks. Ivabradine is an oral drug that inhibits electric signals in the heart, thus reducing the long-term pulse rate. It was developed by Servier Laboratories, a French pharmaceutical company, but Amgen has a license to market it in the United States. The drug is sold under a variety of commercial names in Europe and Asia. The FDA’s fast-track status is designed to expedite development and review of a drug to treat a serious condition and fill an unmet medical need. It means ivabradine could get priority review for approval. Amgen plans to file for FDA approval in the second quarter of 2014. “Amgen looks forward to working closely with the FDA to potentially bring this treatment option to patients with chronic heart failure in the U.S.,” the company said in a statement. About 26 million people have chronic heart failure worldwide, including 5.1 million in the United States. Shares of Amgen closed down Thursday 8 cents or less than 1 percent to $155.46 in trading on the Nasdaq. Markets were closed for Good Friday.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.

Featured Articles

Related Articles